WWWalter Alexander Wohlgemuth

Walter Alexander Wohlgemuth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Walter Alexander Wohlgemuth has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trametinib for the treatment of advanced stage patients with arterio-venous malformations

    by Beatrix Cucuruz, Andreas Deistung, Oleksandr Bidakov, Octavian Andercou, Thomas Schmitz-Rixen, Julius Loeser, Celia Inselmann, Michael Koller, Walter Alexander Wohlgemuth

    Summary: Background: Arterio-venous malformations (AVMs) may lead to vessel aneurysms and thus to life-threatening bleeding or malperfusion of the extremities, causing recurrent ulceration. Possible therapies are embolisation and/or resection. This study investigates treatment options for patients with AVM Schobinger stage III and IV for whom embolisation and resection are no longer possible and medical treatment with trametinib, a mitogen-activated protein kinase inhibitor (MEK) was performed. Patients and methods: As part of the German guideline development process for the diagnosis and treatment of vascular malformations (AWMF register number 003-007), a systematic literature search was performed using a professional service provider, followed by a retrospective, exploratory analysis based on a consecutive local registry at an interdisciplinary tertiary care center for vascular anomalies. All patients with AVM Schobinger stage IIII – IV were included. Results: Of the 559 reports on specific medications for vascular malformations, only 4 (0.7%) included treatment with trametinib, and only 2 (0.4%) of them addressed its use in AVMs showing reduced blood inflow in the malformation or volume reduction. In our case series of 99 consecutive patients with AVM Schobinger stage III–IV, nine were treated with trametinib. Out of them, 6/9 (66%) had ulceration. 1/6 (20% of the patients with ulceration died, one patient required major amputation, and 4 (60%) were healed without recurrence through treatment. Three patients with chronic pain showed reduced symptoms without requiring additional analgesics. Conclusions: The single cases found in the literature and our small case series suggest that MEK1-inhibitors, such as trametinib, are an option for treating AVM Schobinger stage III – IV. Further large-scale studies are required to confirm these initial observations and to fully explore the potential of MEK1-inhibitors.


  • Klippel-Trénaunay-Syndrom

    by Christina Loberg, Walter A. Wohlgemuth, Beatrix Cucuruz

  • Venöse Malformationen

    by Walter A. Wohlgemuth, Christina Loberg, Beatrix Cucuruz

  • Open Access

    Multimodal Diagnostics in Post-COVID: protocol of a matched-pair case-control study (Preprint)

    by Andreas Posa, Walter Alexander Wohlgemuth, Alexander Gussew, Anne Slawig, Lars Reinhardt, Andreas Deistung, Maik Rothe, Andrii Starenkyi, Stefan Schob, Heidi Hellmann, et al.

  • Open Access

    Fast 3D UTE in vivo T 1 and T2*$ {\mathrm{T}}_2^{\ast } $ mapping of fast relaxing knee tissues at 3 T

    by Maik Rothe, Selina Riedel, Anne Slawig, Andreas Deistung, Klaus Bohndorf, Richard Brill, Walter A. Wohlgemuth, Alexander Gussew

    Purpose: UTE MR imaging captures quantitative signals in fast‐relaxing tissues, enabling anatomical visualization and quantitative assessment of T 1 and relaxation times. However, the clinical application of quantitative UTE MRI is limited by long acquisition times. Therefore, this study introduces a novel UTE‐based method for T 1 and mapping, achieving submillimeter resolution in less than 10 min. Theory and Methods: The method employs a dual‐echo acquisition for fast mapping, augmented by an additional acquisition with different T 1 weighting. This second scan enables the computation of signal ratios between scans with different T 1 ‐weighting. These measured signal ratios are then compared to a lookup table containing distinct ratios, corresponding to discrete T 1 values. The approach was validated in phantom solutions mimicking various T 1 and times and applied in vivo to quantify relaxation times across different knee tissue compartments in healthy individuals. Results: The method demonstrated its reliability for T 1 and quantification in rapidly relaxing tissues (1–11 ms). However, it exhibited a tendency to underestimate in skeletal muscle. This limitation arises from the chosen TEs being inadequate to capture slow signal decays. In accordance with the findings of preceding studies, this in vivo study identified three distinct T 1 categories of tissue characterized by short (adipose tissue), moderate (ligaments, tendons, and menisci), and long (skeletal muscle) T 1 values. Conclusion: The presented technique for combined T 1 and mapping enables relaxometry in rapidly relaxing tissues, indicating potential for advanced tissue characterization in clinical settings.


  • Open Access

    Bilateral Cerebral Calcifications in Secondary Fahr’s Syndrome

    by Andreas Posa, Stefan Schob, Walter A. Wohlgemuth, Malte E. Kornhuber

    Fahr’s syndrome is a rare, slowly progressive neurodegenerative disorder characterised by bilateral cerebral calcifications, mostly in the basal ganglia. These cerebral calcifications are composed of calcium and phosphate and are the result of disturbances in calcium‐phosphate homeostasis. The clinical manifestations include neurological, neurocognitive and psychiatric symptoms. This article describes three rare cases of pronounced bilateral cerebral calcifications. All three patients were admitted to the hospital due to a first‐time epileptic seizure. In all three cases, laboratory tests showed significant hypocalcaemia, and cerebral computed tomography showed pronounced bilateral cerebral calcifications in various brain areas. After calcium substitution and anticonvulsant treatment, the patients returned to their prehospital condition and were discharged home seizure free. The aim of this article is to highlight the clinical importance of long‐term follow‐up biochemical laboratory testing and neurocranial imaging in high‐risk patients (e.g., after thyroidectomy) to prevent avoidable neurological and psychiatric complications through pharmaceutical and nutritional substitution therapy.